Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can “Novel-Novel” Drug Development Work? Deals Of The Week Considers Merck’s New Play

Executive Summary

Partnering its PD-1-specific antibody candidate with three other companies, Merck indicates a new era may have arrived for testing novel agents in combination. Also, NIH partners with 10 biopharmas to transform the discovery model and Myriad moves to buy Crescendo.

You may also be interested in...



Deal Watch: Allergan Diversifies With Deals For Migraine Therapies, Ophthalmologic Device

AMAG adds to its commercial and technological capabilities with a buyout of Cord Blood Registry. Meanwhile, ramifications of the GSK/Novartis asset swap from March continue, with GSK divesting a pair of vaccines to Pfizer, while Novartis acquires Australian biotech Spinifex.

Merck Bets Big On Oncology In New R&D Strategy

The big pharma will establish a new oncology unit focused on bringing its anti-PD-1 immunotherapy MK-3475 to market as part of a massive R&D overhaul aimed at lowering costs while driving innovation. Merck isn’t one of the industry’s leading oncology players and may not have as much R&D expertise in the area as rivals, but it might not ultimately matter – as long as MK-3475 gets to market.

Co-Development Guidance Gives More Attention To IND, NDA/BLA Submissions

In a final guidance on co-development of two or more investigational new drugs for use in combination, FDA lays out general principles for IND and marketing application submissions, a topic on which the agency essentially punted in a December 2010 draft document.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS055919

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel